Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. on November 17, 2017, reporting events occurring on November 14, 2017. The Company is an emerging growth company incorporated in Delaware. The filing addresses a critical regulatory issue regarding the Company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or debt figures. However, it discloses historical stockholders' equity balances which are central to the delisting notice:
- March 31, 2017: $(2.7) million
- June 30, 2017: $0.4 million
- September 30, 2017: $(6.1) million
The Company failed to meet the Nasdaq minimum stockholders' equity requirement of $2.5 million.
Material Changes and Events
On November 14, 2017, the Nasdaq Staff notified the Company that it had failed to regain compliance with the Stockholders' Equity Requirement despite a previous extension period ending November 15, 2017. The Staff determined to seek delisting of the Company's securities unless a hearing is requested. The Company had previously regained compliance in May 2017 following an underwritten public offering and changes in warrant liability fair value, but fell out of compliance again by August 2017.
Outlook, Risks, and Management Commentary
Management Action: The Company intends to request a hearing before a Nasdaq Hearings Panel. This request will stay any suspension or delisting action pending the hearing. The Panel has the authority to grant an additional extension of up to 180 calendar days from November 14, 2017, to regain compliance. The Company is working with advisors to prepare a compliance plan.
Risks and Contingencies: If delisted, the Company faces significant risks including:
- Difficulty in buying or selling securities and obtaining accurate quotations.
- A material decline in the price of the Company's securities.
- Impaired ability to raise capital.
Investor Verification Checklist
- Verify the status of the hearing request with the Nasdaq Hearings Panel.
- Monitor the Company's plan of compliance to determine if it will meet the $2.5 million equity requirement within the potential 180-day extension.
- Assess the impact of potential delisting on the liquidity and trading price of the stock.
- Review upcoming capital raising activities to address the negative stockholders' equity position.